期刊文献+

血清CA125监测卵巢上皮性癌术后复发界值探讨 被引量:3

Cut-off value of serum CA125 for monitoring the recurrence of epithelial ovarian carcinoma
原文传递
导出
摘要 目的探讨CA125在监测卵巢上皮性癌术后复发的界值。方法回顾性总结分析四川大学华西二院2005年1月至2009年12月收治的卵巢上皮性癌170例手术后患者,未复发组135例,复发组35例,以绝经后体格检查正常的105例妇女及除卵巢恶性肿瘤之外的65例术后无复发的妇科恶性肿瘤患者作为对照组。以CA125值为5kU/L、10kU/L、15kU/L、20kU/L、25kU/L、30kU/L、35kU/L分别作为界值,比较各界值对判断卵巢上皮性癌术后复发的敏感度、特异度。结果卵巢上皮性癌术后无复发患者、绝经后妇女及妇科恶性肿瘤术后患者CA125中位数值分别为7.5kU/L、8.4kU/L、6.9kU/L;均数±标准差分别为(8.3±3.6)kU/L、(9.1±4.2)kU/L、(7.3±2.6)kU/L。以15kU/L为界值判断复发,敏感度、特异度分别为74.3%、97.0%。结论以15kU/L为CA125界值配合影像学检查监测卵巢上皮性癌术后病情变化,敏感度提高,能够早期发现微小癌灶存在,早期治疗,延长患者生存期。 Objective To explore the relationship between the cut-off value of CA 125and the recurrence of epithelial o- varian carcinoma. Methods Analyze 170 postoperative patients of epithelial ovarian carcinoma retrospectively, consisting of 135 non-recurrent and 35 securrent cases, while !05 cases of menopausal women and 65 cases of postoperative patients of gynecological malignancies except ovarian carcinoma served as control group. Cut-off values of 5, 10, 15, 20, 25, 30, and 35 kU/L were used to compare sensitivity, and specificity. Results The median value of CA125 for non- recurrent patients was 7.5 kU/L; 8.4 kU/L for menopausal women ; 6.9 kU/L for postoperative patients of other gyneco- logical malignancies, whereas the x + s was ( 8.3 ±3.6) kU/L, (9. 1±4. 2 ) kU/L, and ( 7.3 ±2. 6) kU/L, respectively. The cut-off value of 15 kU/L produced the following results: 74. 3% sensitivity, 97.0% specificity. Conclusions When 15 kU/L was used as the cut-off value combined with image examination, the sensitivity increased. This result may improve the prognosis for recurrent patients because of the early detection of recurrent lesions and early retreatment.
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2011年第10期757-760,共4页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 界值 CA125抗原 卵巢上皮性癌 复发 绝经期 cut-off level CA125 antigen epithelial ovarian carcinoma recmTence menopause
  • 相关文献

参考文献5

  • 1RC Bast Jr,TL Klug,ES John, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer[ J]. N Engl J Med, 1983,309:887-890.
  • 2中华医学会妇产科学分会妇科肿瘤学组,沈铿,郎景和.复发性卵巢恶性肿瘤的诊治规范(建议)[J].中华妇产科杂志,2003,38(11):717-719. 被引量:46
  • 3Low RN, Duggan B, Barone RM, et al Treated ovarian cancer MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year [ J]. Radiology 2005,235 ( 3 ) : 918-944.
  • 4Garcia-Velloso M J, Jurado M, Ceamanos C, et al. Diagnostic ac curacy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma [ J ]. European Journal of Nuclear Medicine & Molecular Imaging,2007,34 ( 9 ) : 1396-1801.
  • 5Hellstrom I, Raycraft J, Hayden-Ledbetter M, eL al. The HE4- (WFDC2) protein is a biomarker for ovarian carcinoma[ J ]. Cancer Res,2003 ,63 :3695-3700.

共引文献45

同被引文献24

  • 1Tang MK,Zhou HY, Yam JW,et al. c -Met overexpressioncontributes to the acquired apoptotic resistance of non-ad-herent ovarian cancer cells through a cross talk mediated byphosphatidylinositol 3-kinase and extracellular signal-regu-lated kinase 1/2[ J) . Neoplasia,2010,12(2) : 128-138.
  • 2Mackay HJ,Brady MF’Oza AM,et al. Prognostic relevanceof uncommon ovarian histology in woman with stage HI/IVepithelial ovarian cancer[ J] . Int J Gynecol Cancer, 2010,20 (6) :945-952.
  • 3Gardner GJ, Baser RE, Brady MF, et al. CA125 regressionin ovarian cancer patients treated with intravenous versusintraperitoneal platinum-based chemotherapy .. a gynecologiconcology group study[ J]. Gynecol Oncol, 2012 ,124 ( 2 ):216-220.
  • 4Bast R C Jr, Klug T L, St John E, et al. A radioi- mmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer [ J ]. N Engl J Med, 1983,309(15) :883-887.
  • 5Makar A P, Kristensen G B, Bormer O P,et al. CA 125 measured before second-look laparotomy is an indep- endent prognostic factor for survival in patients with epithelial ovarian cancer [ J ]. Gynecol Oneol, 1992,45 ( 3 ) : 323 -328.
  • 6iu P Y, Alberts D S, Monk B J, et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy [ J ]. J Clin Oncol, 2007, 25 ( 24 ) : 3615-3620.
  • 7Prat A, Parera M, Adamo B, et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels[ J]. Ann Oncol,2009 ,20 :294-297.
  • 8Wilder J L, Pavlik E, Straughn J M, et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a prel- iminary investigation [ J ]. Gynecol Oncol, 2003,89 ( 2 ) : 233 -235.
  • 9Bese T,Demirkiran F,Arvas M,et al. What should be the cut-off level of serum CA125 to evaluate the disease status before second look laparotomy in epithelial ovarian carcinoma [ J ]. Int J Gynecol Cancer, 1997,7 ( 1 ) :42-45.
  • 10王新宇,叶菁,冯素文,吕卫国,万小云,谢幸.血清CA125水平测定在预测卵巢上皮性癌复发和预后中的价值[J].中华妇产科杂志,2010,45(11):813-816. 被引量:28

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部